Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

A bit more!

$Aldeyra Therapeutics (ALDX.US)$ Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5213 Views
Comment
Sign in to post a comment